Related Experiment Video
Updated: Dec 25, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.9K
Cesium-131 prostate brachytherapy: A single institutional long-term experience.
Ronald M Benoit1, Zachary D Horne2, Christopher J Houser3
1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Brachytherapy
|April 7, 2020
Summary
Prostate brachytherapy with Cesium-131 (131Cs) offers excellent long-term biochemical control for prostate cancer patients. This study shows high rates of disease freedom across risk groups, highlighting its effectiveness.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Prostate seed implant (PSI) using Cesium-131 (131Cs) is a treatment option for prostate cancer.
- Assessing long-term outcomes of 131Cs PSI is crucial for treatment planning.
Purpose of the Study:
- To evaluate prostate-specific antigen (PSA) outcomes in men treated with 131Cs PSI.
- To report on biochemical freedom from disease (BFD) rates based on NCCN risk stratification and treatment modalities.
Main Methods:
- Retrospective analysis of 669 patients treated with 131Cs PSI.
- Follow-up duration ranged from 0-144 months (median 60.0 months).
- Biochemical freedom from disease (BFD) defined by the Phoenix criteria.
Main Results:
- Excellent 5/10-year BFD rates: 97.1%/95.3% (low-risk), 94.0%/90.1% (intermediate-risk), and 86.2%/56.6% (high-risk).
- PSA ≤0.2 ng/dL at 4 years predicted 10-year biochemical control (96.3% vs 70.4%, p < 0.001).
Conclusions:
- Prostate brachytherapy with 131Cs demonstrates robust long-term biochemical control.
- 131Cs PSI is an effective treatment for prostate cancer across various risk categories.
